Ernexa Therapeutics Inc. (ERNAW) — 8-K Filings

8-K Filings (19)

• Ernex Therapeutics Files 8-K — Dec 11, 2025 Risk: low
  On December 11, 2025, Ernexa Therapeutics Inc. filed an 8-K report. The filing primarily serves as a notification of financial statements and exhibits, and a Re
• Ernexia Therapeutics Changes Certifying Accountant — Jul 7, 2025 Risk: low
  Ernexia Therapeutics Inc. filed an 8-K on July 7, 2025, reporting a change in its certifying accountant as of June 30, 2025. The company, previously known as Et
• Ernexia Therapeutics Files 8-K with Amendments and Exhibits — Jun 12, 2025 Risk: low
  Ernexia Therapeutics Inc. filed an 8-K on June 12, 2025, reporting amendments to its Articles of Incorporation or Bylaws and filing financial statements and exh
• Ernex Therapeutics Files 8-K on Equity Sales — Jun 9, 2025 Risk: medium
  On June 9, 2025, Ernexa Therapeutics Inc. filed an 8-K report detailing unregistered sales of equity securities and other events. The company, formerly known as
• Ernexia Therapeutics Files 8-K on Corporate Matters — Jun 2, 2025 Risk: low
  Ernexia Therapeutics Inc. filed an 8-K on June 2, 2025, reporting on amendments to its articles of incorporation or bylaws, submission of matters to a vote of s
• Eterna Therapeutics Files 8-K: Material Agreement, Equity Sales — Apr 3, 2025 Risk: medium
  Eterna Therapeutics Inc. filed an 8-K on April 3, 2025, reporting on events as of March 31, 2025. The filing indicates an entry into a material definitive agree
• Eterna Therapeutics Files 8-K for Bylaws and Financials — Mar 26, 2025 Risk: low
  Eterna Therapeutics Inc. filed an 8-K on March 26, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The company,
• Eterna Therapeutics Enters Material Definitive Agreement — Mar 24, 2025 Risk: medium
  Eterna Therapeutics Inc. entered into a material definitive agreement on March 20, 2025. This agreement creates a direct financial obligation or an obligation u
• Eterna Therapeutics Files 8-K on Shareholder Nominations — Feb 13, 2025 Risk: medium
  Eterna Therapeutics Inc. filed an 8-K on February 13, 2025, reporting shareholder nominations for its upcoming meeting. The filing indicates that the company, f
• Eterna Therapeutics Faces Nasdaq Delisting, Board Changes — Jan 10, 2025 Risk: high
  Eterna Therapeutics Inc. announced on January 3, 2025, that it received a notice from the Nasdaq Stock Market indicating a failure to meet continued listing req
• Eterna Therapeutics Faces Delisting Concerns — Jan 3, 2025 Risk: high
  Eterna Therapeutics Inc. filed an 8-K on January 3, 2025, reporting a notice of delisting or failure to meet continued listing requirements as of December 30, 2
• Eterna Therapeutics Files 8-K with Key Corporate Updates — Oct 29, 2024 Risk: medium
  Eterna Therapeutics Inc. filed an 8-K on October 29, 2024, reporting on several key events. These include entering into a material definitive agreement, unregis
• Eterna Therapeutics Terminates Material Definitive Agreement — Sep 27, 2024 Risk: medium
  Eterna Therapeutics Inc. announced on September 24, 2024, the termination of a material definitive agreement. The company, formerly known as Brooklyn ImmunoTher
• Eterna Therapeutics Reports Material Agreement and Financial Obligations — Sep 25, 2024 Risk: medium
  Eterna Therapeutics Inc. announced on September 24, 2024, that it entered into a Material Definitive Agreement. The company also reported the creation of a Dire
• Eterna Therapeutics Faces Nasdaq Delisting — Sep 23, 2024 Risk: high
  Eterna Therapeutics Inc. received a notice on September 17, 2024, indicating it failed to meet the continued listing standards of the Nasdaq Capital Market. The
• Eterna Therapeutics Sells Subsidiary — Aug 19, 2024 Risk: medium
  Eterna Therapeutics Inc. announced on August 16, 2024, that it has entered into a definitive agreement to sell its wholly-owned subsidiary, Eterna Therapeutics
• Eterna Therapeutics Faces Nasdaq Delisting Warning — Mar 22, 2024 Risk: high
  Eterna Therapeutics Inc. received a notice on March 19, 2024, indicating it failed to meet the continued listing standards of the Nasdaq Capital Market. The com
• Eterna Therapeutics Announces Leadership Changes & Compensation Arrangements — Feb 16, 2024 Risk: medium
  Eterna Therapeutics Inc. reported on February 12, 2024, the departure of directors or certain officers and the election or appointment of others, along with com
• Eterna Therapeutics (ERNA) Delisted from Nasdaq — Jan 19, 2024
  Eterna Therapeutics Inc. (ERNA) announced on January 17, 2024, that its common stock will be delisted from The Nasdaq Stock Market LLC. This delisting is due to

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX